MADISON DEAN: Open Payments
NPI 1689416794 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 43 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $293 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 17 | $252 |
| PFIZER INC. | 3 | $73 |
| Astellas Pharma US Inc | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 2 | $59 |
| ABBVIE INC. | 3 | $58 |
| Abbott Laboratories | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Lilly USA, LLC | 2 | $32 |
Products named: Ozempic, PREVNAR 20, Veozah, Rybelsus, VOQUEZNA, TRELEGY ELLIPTA, ZENPEP, VRAYLAR.
Industry payments across AZ — which companies pay providers there.
